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Nullius in verba: Version 2.0 of the University of Minnesota, School of Social and 
Administrative Pharmacy Program, Proposed Guidelines for Formulary Evaluation 
Paul C Langley, PhD, Adjunct Professor, College of Pharmacy, University of Minnesota 
 
Abstract 
The principal objective in introducing Version 2 of the proposed Minnesota Guidelines for Formulary Evaluation is to recognize the 
challenges faced by formulary committees and other health care decision makers with the introduction of next generation 
sequencing (NGS) in therapy choice across a range of disease areas. The adoption of NGS promises to disrupt accepted standards in 
product development and formulary assessment. Although the standards expected in presenting, evaluating and replications clinical 
and cost-effective claims will still be central to the assessment process, the application of NGS platforms to link therapy choices to 
identified mutation clusters will require a robust evidence base. These Guidelines are intended to provide the framework for that 
evidence base by setting protocol driven standards for (i) choosing the appropriate NGS platform and (ii) evaluating NGS platforms in 
the identification of therapy pathways for target populations in disease states.    
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INTRODUCTION 
The theme that links Version 1.0 and Version 2.0 of the 
Minnesota proposed Guidelines for Formulary Evaluation is 
the importance of establishing a robust, coherent and 
growing evidence base to support therapy decisions 1  2 . This 
evidence base applies not only to claims for clinical efficacy 
and effectiveness but also for claims for cost-effectiveness 
and budget impact. If health technology assessments are to 
inform resource allocation in health care, then these 
assessments must be defensible. They must meet the 
standards of normal science. Claims must be credible, 
evaluable and replicable 3 4. Unfortunately, over the last 20 
years the focus of health technology assessments (otherwise 
referred to by the unfortunate term pharmacoeconomics) 
have put credibility, evaluation and replication on one side in 
favor of the construction of what have been described as 
imaginary worlds 5. These imaginary modeled claims are best 
exemplified in the reference case methodology set center 
stage by the National Institute for Health and Care Excellence 
in the UK 6. By construction, reference case claims, notably in 
the case of chronic disease, ask manufacturers and their 
ready helpers in consulting to construct lifetime or long term 
cost-utility models where the acceptance or otherwise of a 
new therapy is judged by its ability, over 20 or 30 or even 
more years of the model treatment cohort to meet 
discounted cost-per-quality adjusted life year (QALY) 
willingness to pay thresholds. They were never intended to 
support claims evaluation or replication 7 8. 
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The willingness to suspend belief in the empirical assessment 
of comparative therapy claims, to opt for pseudoscience 
rather than science, intelligent design rather than natural 
selection, is not confined to the UK. Reference case model 
standards have been adopted in Ireland and New Zealand, 
proposed as the basis for health technology assessment in 
the European Union and underpin standards established by 
the Academy of Managed Care Pharmacy (AMCP) in the US 
and, on a more global stage, the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) 9 10 11 12 
13 14.  Although there is little if any interest in the US in 
modeled reference case claims utilizing QALY estimates, the 
Institute for Clinical and Economic Review (ICER) has 
developed an audience for such claims 15. The fact that these 
fail to meet the standards of normal science appears to have 
been overlooked.  
 
To add a further element to the support for non-evaluable 
claims, the editors of leading technology assessment journals, 
Value in Health, Pharmacoeconomics and the Journal of 
Medical economics have published, and continue to publish 
reference case models with claims expressed in non-
evaluable cost-utility terms 16 17 18. It is unclear whether these 
analyses resonate with health care decision makers to have 
even a minimal impact of formulary decisions. 
 
Against this, admittedly depressing, background the 
Minnesota Guidelines have attempted to make the case for 
hypothesis testing in formulary assessments, arguing that 
long-term reference case models should be abandoned in 
favor of short term evaluations that are credible, evaluable 
and replicable. Claims that can be assessed and the results 
reported to formulary committees, treating physicians and 
patients. While this does not deny the contribution of 
retrospective assessment of drug impacts in target 
populations, the fact remains that unless claims for new 
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therapies and models of therapy choice are not put in 
evaluable and replicable terms, then we lack a robust basis 
for formulary and treatment decisions.  
 
THE CHALLENGE OF NEXT GENERATION SEQUENCING  
Version 1.0 of the Minnesota Guidelines was focused on the 
evidentiary standards required to support informed choice in 
the selection of single therapies. Following, the classical 
comparative randomized clinical trial (RCT) model, the 
standards proposed for claims credibility, evaluation and 
replication in formulary submissions were to provide 
feedback to formulary committees in a short-term timeframe 
following product launch. To accomplish this, the Guidelines 
proposed that formulary submissions be accompanied by a 
study protocol detailing how the claims for clinical outcomes, 
cost-effectiveness and budget impact, were to be evaluated. 
The Guidelines did not suggest that formulary listing be 
contingent upon feedback from the implementation of the 
study protocol, but that the claims should be considered 
provisional. Until an assessment of the claims was made, 
formulary positioning, pricing and the role of the products in 
treatment guidelines would be treated with caution. In part, 
this emphasis on evaluation and replication reflected long-
term and growing concerns over the limited evidence base 
supporting all too many clinical claims with the difficulties 
independent assessors had in replicating claims.   
 
The uptake of next generation sequencing (NGS) platforms, in 
linking mutation expression to therapy choices, promises to 
make the need for claims feedback even more pressing 19 20. 
Rather than single product claims, with a low response rate, 
NGS assessments propose to link sub-populations within the 
target population to single or combination therapies. The 
presumption being that targeting specific mutation or 
mutation clusters will improve overall response and possible 
reduce treatment costs. Hence the perceived need for 
Guidelines to set the evidence standards to support the 
application of specific NGS therapy choice claims to target 
populations within disease areas.  
 
As described in the Background (Section 1) of Version 2.0 of 
the guidelines, the challenge of NGS lies: (i) in the standards 
required for an NGS platform and the choice between 
platforms; and (ii) the evaluation of platform-driven therapy 
choices. These are decisions a formulary committee will have 
to make, let alone acceptance by treating physicians and 
patients, and panels charged with treatment guideline 
recommendations. The decisions must be evidence-based 
and we do not have the luxury, if we ever did, of developing 
reference case models that generate non-evaluable claims. 
 
STRUCTURE OF THE GUIDELINES 
The Guidelines are in six sections. These are: 
1. Background 
2. Evaluating Formulary Submissions: Key Elements 
3. Value and Cost Outcomes Claims 
4. Product and Comparator Assessment Protocol 
5. Next Generation Sequencing Platform 
Assessment Protocol 
6. Requests for Submissions 
Section 1: Background 
The focus of this section is on the importance of presenting 
claims for competing therapy interventions that are credible, 
evaluable and replicable. This applies with equal force to 
single product claims, whether or not they have genetic 
targets or simply target populations defined by clinical 
characteristics, as well as to claims from NGS. In the latter 
case, the assessment of competing therapy claims involves a 
number of reference points: (i) the standard of care as 
defined by a treatment guideline or options within this 
general reference point; (ii) therapy claims for the individual 
therapy pathways defined by an NGS platform that links 
mutation clusters to drug combinations (or single therapies) 
where the reference point may be the therapy pathways 
generated by a competing NGS platform; and (iii) the overall 
therapy outcomes and costs for all therapies identified for 
the target population by the NGS platform.  
 
Four types of formulary submission are identified: (i) standard 
submission for single drug products where the target 
population is defined in clinical or behavioral terms; (ii) single, 
molecule submissions where the drug target is the expression 
of a single molecule or gene mutation; (iii) NGS platform 
submissions where the formulary committee is judging the 
relative merits of competing platforms; and (iv) therapy 
target submissions where an NGS platform is supporting 
therapy choices matched to individual mutation clusters. 
 
The background section also considers a number of other 
issues. Possibly the most important is the question of NGS 
uptake. There are substantial barriers to the willingness of 
formulary committees, physicians, patients and guideline 
panels to accept the ‘promise’ of NGS in therapy choice and 
the assumed benefits conferred on patients. If NGS is to be 
accepted, and that means going beyond getting a platform 
approved by the Centers for Medicare and Medicaid Services 
(CMS) or the Food and Drug Administration (FDA), then 
platform developers will have to invest in a research program 
to demonstrate that their platform yields clinically 
meaningful outcomes across a range of disease states and 
target populations. At the present, this is far from being 
achieved. After all, the evidence base for all too many 
pharmaceutical products is thin with substantive issues, as 
the Guidelines point out, concerning the failure to replicate 
phase 3 claims. 
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A further issue is the identification of the target population 
for drug product and NGS platform assessment. This is not 
simply an issue of a clinical or genomic profile by stage of 
disease, but a framework that identifies the major outcomes 
in the disease state (e.g., median survival in late stage cancer) 
and the direct medical costs of treatment. This should be 
identified in terms of treatment guidelines that map disease 
progression and indicate at which disease stage an NGS 
assessment would be appropriate.  
 
In addition, an aspect of therapy intervention that is often 
overlooked is the presence of comorbidities. In older 
populations, where it is expected (or hoped) that NGS 
treatment choices may have a significant impact, patients will 
typically present with one or more comorbidities. A 
treatment intervention, therefore, needs to accommodate 
comorbidities and assess the extent to which the presence 
and treatment of comorbidities may qualify NGS claims. 
 
NGS claims should also take account of the impact of therapy 
choices on side effects. In particular, toxicity of the proposed 
therapy and the experience (and management) of pain in late 
stage cancer.   
 
Adherence to and persistence with therapies are also a key 
issue. These are seldom factored into modeled claims and are 
obscured by trial protocols. However, with the potential for 
toxicity and adverse side effects from NGS driven therapy, in 
particular combination therapy for complex mutation targets, 
the issue of early discontinuation should be addressed.   
 
Section 1 also points to the need for a robust evidence base; 
an evidence base that meets recognized standards for: (i) 
diagnostic accuracy and quality; (ii) systematic reviews; (iii) 
reporting randomized trials (e.g., multiple platform basket 
trials); (iv) application of evidence hierarchy criteria; and (v) 
standards for evidence to support treatment guideline 
recommendations (e.g., National Cancer Comprehensive 
Network). 
 
Section 2: Evaluating Formulary Submissions: Key Elements 
The next section of the Guidelines considers key elements in 
evaluating formulary submissions for both single products 
and NGS platforms. These are: 
• Product and comparator descriptions and 
pricing for individual drugs and NGS 
platforms 
• Descriptions of target populations and sub-
populations 
• Evidence for significant adverse events and 
contraindications 
• Primary and secondary outcomes  
• Evidence from direct and indirect 
comparisons 
• Replication of product claims and NGS 
platform curating 
• Adherence and persistence 
• Evidence summaries for drug product 
comparisons and for competing NGS 
platforms 
Section 3: Value and Cost-Outcomes Claims 
Claims for drug product or NGS platforms should meet the 
evidence standards for credibility, evaluation and replication. 
At the same time, all claims evaluations should provide 
feedback to decision makers in a meaningful time horizon. In 
practice, this means less than two years. The claims for 
individual therapy pathways should be presented and 
evaluated to the same standards for individual drug product 
claims against comparator therapies. The only difference is 
that those marketing an NGS platform should report on both 
the clinical and cost-effectiveness claims for each pathway as 
well as for the therapy pathways overall. As detailed in 
sections 4 and 5, a claims evaluation protocol is a required 
component of these assessments. 
 
There is no fixed format for the framework submitted for 
claims assessment. Claims can be based on the results of 
RCTs with a model driven by the RCT protocol or as short 
term models. Markov processes are not excluded or even 
discrete event simulation. The objective after all is not to 
justify a model structure but to present a coherent basis for 
establishing claims which can be evaluated, reported on and 
replicated. 
 
It is at the discretion of those making the submission as to the 
choice of outcomes. Clearly, there are outcomes common to 
many disease states which may be considered ‘standard’. 
Even so, other outcomes may be considered relevant such as 
patient satisfaction and quality of life. Where patient 
reported outcomes are proposed as part of the assessment 
protocol detail should also be provided on how they are to be 
assessed. There are, for example, a range of QALY measures 
none of which are typically collected as part of electronic 
records. If a prospective observational tracking is proposed 
for an NGE platform, then it needs to be demonstrated how 
these various measures are to be reported. 
 
The standards also ask for adherence and persistence to be 
modeled explicitly. This reflects the evidence across many 
disease states than within as short a period as two years, the 
majority of patients are either non-adherent to therapy or 
have discontinued therapy 21. Where an NGS platform is 
driving therapy choice, adherence and persistence should be 
tracked for each arm over the study period. 
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Section 4: Product Claims Assessment Protocol 
A submission should be considered incomplete if it is not 
accompanied by a claims assessment protocol. The protocol 
standards for claims assessment for both individual drug 
products and NGS platforms for target populations in disease 
area follow from the PROST protocol presented in Version 1.0 
of the Guidelines  22. A format for protocol assessment is 
provided which has been amended from the previous 
recommended protocol to include NGS platform application 
and NGS platform choice. This is followed by a series of 
questions a formulary committee should ask to ensure the 
submission meets the required standards. These questions 
are: 
• Has the submission detailed the study objectives? 
• Has the submission provided a context for the 
protocol claims assessment? 
• Has the submission identified a target population 
rationale and description? 
• Have the proposed claims been detailed?  
• Has the submission defended the choice of study 
design? 
• Has the submission detailed how the study is to be 
implemented and feedback provided? 
Section 5: Next Generation Sequencing Platform Assessment 
Protocol 
This section focus on the standards to be applied by 
formulary committees in the choice of NGS platform. Given 
the number of platforms likely to appear in the next few 
years, it would be foolhardy to assume that all platforms are 
similar in their identification of mutations and proposed 
matching to therapy choices. Formulary committees need to 
be assured that the platform is effectively curated and the 
library maintained. There is also, of course, the possibility 
that NGS platforms may be disease specific. The standards for 
claims evaluation and replication apply equally to 
comparative assessments of NGS platforms as they do to 
evaluating the impact of drug and therapy options for target 
populations. 
 
A submission structure for comparative NGS platform 
assessment is provided together with questions a formulary 
committee might consider to assess the content and quality 
of the submission protocol. The questions are similar to those 
detailed in Section 4.0: 
• Has the comparative assessment detailed the study 
objectives (e.g., performance standards for NGS 
platforms)? 
• Has the submission indicated why an assessment is 
necessary? 
• Has the submission justified and identified a target 
population for the comparative assessment? 
• Have the claims for comparative assessments been 
detailed? 
• Has a study design and rationale been provided? 
• How is the study to be implemented and the results 
reported?  
Section 6: Request for Submissions 
The final section merely emphasizes that unsolicited 
submissions are not allowed. Submissions should be by 
request whether for a drug therapy or NGS driven therapy, or 
for a comparative NGS platform assessment.  
 
IMPLEMENTING NEW GENERATION SEQUENCING 
It is made explicit in the Guidelines that advocates of NGS are 
going to face two hurdles before health systems will be 
willing to introduce NGS even on a limited scale for specific 
target populations. The first of these is the need for a robust 
evidence base. So far this does not exist. Essentially, all we 
have are phase 2/3 RCT claims and some observational data 
on single gene targeted therapy. This is a far cry from NGS 
and represents more an unwillingness to reject the classic 
phase 3 RCT design than a recognition that if therapy 
interventions are to be accepted they must address the range 
of mutation heterogeneities in, for example, late stage hard 
tumor interventions. Second, NGS developers need to invest 
in a research program that evaluates their platform against 
competing platforms in therapy choice in a range of target 
populations. Given the complexity of mutation loads and the 
presence of multiple mutations for individual patients with a 
similar hard tumor diagnosis, formulary committees would be 
unwise to assume that robust evidence for a platform and the 
matched mutations to therapy choices in one disease area 
would necessarily translate to a similar robust outcome in 
other disease states.  
 
The protocols proposed in the Guidelines will go some way to 
meeting these evidence requirements. This does not mean 
that a demonstration can wait until a platform has been 
approved for a target population. The presumption is that the 
manufacturers of the various platforms will have already 
invested in phase 3 or equivalent basket trials to support 
their claims. 
 
The need to develop a robust evidence base also puts 
pressure on drug manufacturers to develop the appropriate 
trial frameworks to support the place of a new compound in 
therapy. With the distribution of mutations driving therapy 
choice it may well be that a new compound, given choice of 
NGS platform, will be not only targeted to specific mutations 
but may also have to be part of a combination therapy 
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package for that sub-population of patients in the target 
group. 
 
Even so, the onus is still on the commitment by NGS 
manufacturers and, to a lesser extent, pharmaceutical 
manufacturers and biotechnology companies to commit to an 
investment in robust basket trials and observational studies. 
Unless a high quality evidence base is available, health 
guideline panels are unlikely to agree on the place of NGS in 
therapy. Whether NGS manufacturers will commit to this is a 
moot point. The business model may not have captured this 
aspect of an evidence base. The manufacturers may have 
thought solely in terms of putting a platform on the market. If 
so, it is unlikely to become a commercial success.   
 
CONCLUSIONS 
At this juncture it is unclear as to how widely and how quickly 
NGS will be taken up. In the absence of a robust evidence 
base, as detailed in these Guidelines, for the clinical and cost-
effective contribution of NGS the take-up is likely to be slow. 
The most promising avenue is probably through a focus of 
NGS in late stage cancers where there are few options and 
the patient has poor survival and quality of life prognoses.  
 
The formulary submission standards proposed here are 
designed to set the parameters for the development of an 
evidence base. This is the critical next step. The evidence 
base for specific platforms needs (i) to differentiate that 
platform from competitors as being ‘first to market’ is no 
guarantee that the drug or NGS platform will be commercially 
successful, and (ii)  to demonstrate that there is value in 
integrating an NGS assessment and linked therapy options 
within specific target populations.  
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